CannPal Animal Therapeutics Limited

CannPal Animal Therapeutics Limited

CannPal Animal Therapeutics Limited (ASX: CP1) is a listed animal health Company developing innovative and naturally derived plant based therapeutic products for pets targeting the Endocannabinoid System that owners can trust are both safe and scientifically validated.
Biotechnology
1d 5d 1m 6m 1y Max

About CannPal Animal Therapeutics Limited

The Company has a research focus on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovate therapeutics that can influence the Endocannabinoid System with full regulatory approval for veterinary distribution.

To provide veterinarians and pet owners with innovative and naturally derived therapeutics to treat pets in a safe and ethical way

To be a global leader in the development of therapeutic products for companion animals using plant compounds that influence the endocannabinoid system > (scope grows);

Team

MARGARET CURTIS
Head Of Clinical Development
JEFFREY SHERMAN
Lead Toxicology
KEVIN WILLARD
Senior Formulations Chemist
LAYTON MILLS
Founder/ Managing Director
GEOFF STARR
Non-Executive Chairman
MAX JOHNSTON
Non-Executive Director
DR KATE ADAMS
Non-Executive Director
ROBERT CLIFFORD
Non-Executive Director
MARA GORDON
Medical Cannabis Adviser
DR TED WHITTEM
Commercial Veterinary Adviser
DR RAYSON TAN
Chief Scientific Officer
Amanda Reiman
Cannabis Regulatory Adviser
$ 0.00
Symbol:
CP1